Skip to main content
. 2021 Aug 20;41(8):BSR20210420. doi: 10.1042/BSR20210420

Figure 6. PTH promoted osteogenic differentiation by activating the JNK MAPK pathway.

Figure 6

(A,B) ALP levels detected by ALP staining and activity assay; mineralized matrix formation assessed by Alizarin Red staining. SP600125, a specific inhibitor of JNK MAPK, depleted the osteogenic ability of PTH under LPS stimulation. Scale bar, 200 μm. (C) Relative ALP, COL1, OPN, OCN, and RUNX2 mRNA amounts evaluated by qRT-PCR suggested that SP600125 reversed the promoting effects of PTH on osteogenesis-related gene expression. (D) Protein levels of ALP, COL1, OPN, OCN, and RUNX2, determined by Western blot analysis, indicated that the inhibition of JNK dampened the expression of osteogenesis-related proteins. (E,F) Expression levels of OCN and RUNX2 revealed by immunofluorescence were lower in the SP600125 (HBMSCs + LPS + PTH + SP600125) group than in the LPS (HBMSCs + LPS + SP600125) group. Scale bar, 50 μm. Data are mean ± SD. **P<0.01 versus the control (HBMSCs) group; #P<0.05 versus the LPS (HBMSCs + LPS) group, n=5.